We searched PubMed and Medline with the term “GVHD” and cross-referenced it with the following words: “clinical”, “cytokines”, “MHC”, “HLA antigens”, “biology”, and “immunology”. We included mostly peer-reviewed original and review journal articles published within the past decade, except for seminal articles that initially described the clinical features. All non-peer-reviewed manuscripts, supplements, and textbooks were excluded.
SeminarGraft-versus-host disease
Introduction
The number of allogeneic haemopoietic-cell transplantations (HCTs) continues to rise, with more than 25 000 procedures undertaken annually. The graft-versus-leukaemia or graft-versus-tumour effect during this procedure effectively eradicates many haematological malignant diseases.1 Development of novel strategies that use donor leucocyte infusions, non-myeloablative conditioning, and umbilical-cord blood transplantation has helped expand the indications for allogeneic HCT over the past few years, especially for older patients.2 Improvements in infectious prophylaxis, immunosuppressive treatments, supportive care, and DNA-based tissue typing have also contributed to enhanced outcomes after the technique.1 Yet, the major complication of allogeneic HCT—graft-versus-host disease (GVHD)—remains lethal and limits use of this important procedure.2 In view of current trends, the number of transplants from unrelated donors is expected to double within the next 5 years, substantially increasing the population of patients with GVHD. In this Seminar, we review advances made in identification of genetic risk factors and pathophysiology of this major HCT complication and its prevention, diagnosis, and treatment.
Section snippets
Cause and clinical features
50 years ago, Billingham formulated three requirements for development of GVHD: (1) the graft must contain immunologically competent cells; (2) the recipient must express tissue antigens that are not present in the transplant donor; and (3) the patient must be incapable of mounting an effective response to eliminate the transplanted cells.3 We know now that the immunologically competent cells are T cells and that GVHD can develop in various clinical settings when tissues containing T cells
Clinical features of acute GVHD
On the basis of early work, acute GVHD was defined as arising before day 100 post-transplant, whereas chronic disease happened after that time.23, 24, 25 This definition is far from satisfactory, and a National Institutes of Health classification includes late-onset acute GVHD (after day 100) and an overlap syndrome with features of both acute and chronic disorder.26, 27 Late-onset acute GVHD and the overlap syndrome arise with greater frequency after reduced-intensity conditioning, an
Clinical features of chronic GVHD
Chronic GVHD is the major cause of late non-relapse death after HCT.40 Its presentation can be progressive (active or acute GVHD merging into chronic), quiescent (acute disease that resolves completely but is followed later by chronic), or de novo. Older recipient age and a history of acute GVHD are the greatest risk factors for chronic disease.41 Therefore, strategies for acute GVHD prevention could help to prevent chronic disease. Panel 2 shows that manifestations of chronic GVHD are somewhat
Pathophysiology of acute GVHD
Two important principles should be considered with respect to the pathophysiology of acute GVHD. First, the disease is indicative of exaggerated but typical inflammatory mechanisms mediated by donor lymphocytes infused into the recipient, in whom they function appropriately in view of the foreign environment they encounter. Second, the recipient's tissues that stimulate donor lymphocytes have usually been damaged by underlying disease, previous infections, and the transplant conditioning
Prevention of GVHD
On the basis of evidence from animal models for the central role of T cells in initiation of GVHD, many clinical studies of T-cell depletion as prophylaxis for the disease were undertaken in the 1980s and 1990s. Three main depletion strategies were studied: (1) negative selection of T cells ex vivo; (2) positive selection of CD34+ stem cells ex vivo; and (3) antibodies against T cells in vivo.82 Most approaches showed substantial limitation of both acute and chronic GVHD.83, 84, 85
Treatment of acute GVHD
GVHD first develops, generally, in the second month after HCT during calcineurin-based prophylaxis.114 Steroids, with their potent anti-lymphocyte and anti-inflammatory activity, are the gold standard for treatment of GVHD. Many centres treat mild GVHD of the skin (grade I) with topical steroids alone, but for more severe disease and any degree of visceral GVHD involvement high-dose systemic steroids are usually initiated. Administration of steroids results in complete remission in less than
Treatment of chronic GVHD
By contrast with acute GVHD, the pathophysiology of chronic GVHD remains poorly understood and the disease is treated with various immunosuppressive agents. The response of chronic GVHD to treatment is unpredictable, and mixed responses in different organs can take place in the same patient. Confounding variables such as infection and comorbidities also make responses hard to measure. Use of corticosteroids (with or without a calcineurin inhibitor) is the standard of care, but findings of a
Essential supportive care in GVHD patients
Meticulous supportive care is vital for patients with both acute and chronic GVHD owing to the extended duration of immunosuppressive regimens and because the many drugs administered could have synergistic toxic effects. Such care includes extensive infectious prophylaxis, early interventions in cases of suspected infections, and prophylaxis against non-infectious side-effects of drugs (table). These complications usually need rapid responses to prevent serious or irreversible damage and are
Future directions
As allogeneic transplantation becomes an increasingly attractive therapeutic option, need for novel approaches to GVHD has accelerated. The number of patients receiving transplants from unrelated donors is expected to double in the next 5 years, substantially boosting the population of patients with GVHD.
The advent of reduced-intensity conditioning regimens has diminished transplant-related mortality and lengthened the period during which acute GVHD can develop (many new cases present up to day
Search strategy and selection criteria
References (139)
- et al.
Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease
Blood
(1986) - et al.
The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation
Blood
(1995) - et al.
HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival
Biol Blood Marrow Transplant
(2007) - et al.
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
Blood
(1998) - et al.
Umbilical cord blood transplantation in adults: results of the prospective cord blood transplantation (COBLT)
Biol Blood Marrow Transplant
(2005) - et al.
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
Blood
(2002) - et al.
Cytokine dysregulation and acute graft-versus-host disease
Blood
(1992) - et al.
Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants
Blood
(1999) - et al.
Non-HLA immunogenetics in hematopoietic stem cell transplantation
Curr Opin Immunol
(2005) - et al.
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Blood
(2005)